Access all of the content
Dr Jennifer Taylor-Cousar (National Jewish Health, Denver, CO, USA) explores what we have learnt so far about how COVID-19 is effecting patients with cystic fibrosis.
1. What is the risk to cystic fibrosis patients from COVID-19 and what have we learned from reported cases so far? (0:07)
2. It seems that, to date, cystic fibrosis patients have only experienced mild symptoms. What do think is the reason for this? (1:08)
3. How are healthcare providers managing the routine care of patients with cystic fibrosis during the pandemic? (2:58)
4. If a cystic fibrosis patient has COVID-19, how does this impact on their day to day treatment? (3:36)
5. How can cystic fibrosis patients with COVID-19 avoid infecting other people while using non-invasive ventilation in a hospital setting? (4:26)
Speaker disclosure: Dr Taylor-Cousar has acted as a PI on studies for Vertex and Proteostasis; a consultant/advisor for Proteostasis, Santhera, 4DMT and Vertex; and a speaker for Vertex. She has also received grant funding from the CF Foundation; serves on the CF Foundation’s Clinical Research Executive Committee and Clinical Research Advisory Board; and is chair-elect of the ATS Clinical Problems Assembly Programming Committee.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Commissioned, edited and supported by Touch Medical Media
Filmed on Thursday 9 April 2020.
Share this Video
Related Videos In COVID-19
Iwein Gyselinck, ERS 2021: DAWn-AZITHRO – Azithromycin for Patients with COVID-19
TouchRESPIRATORY got the opportunity to catch up with Dr Iwein Gyselinck around the DAWn-AZITHRO trial of azithromycin antiviral therapy for patients with COVID-19. The abstract ‘Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof of concept clinical trial.’ (Presentation ID 2666) was presented at ERS International Congress 2021, 5-8 […]
Sara Tomassetti, ATS 2021: Post-COVID-19 Interstitial Lung Syndrome
We were delighted to catch up with Dr Sara Tomassetti (Careggi University Hospital, Florence, Italy) around interstitial lung changes following SARS-CoV-2 infection. The abstract ‘A Multidisciplinary Multicenter Study Evaluating Risk Factors, Prevalence and Characteristics of Post-COVID-19 Interstitial Lung Syndrome PCOILS.‘ (ABSTRACT NUMBER: A1748) was presented at ATS 2021 International Conference, 14-19 May, 2021. Questions What […]
Julie Ake, CHEST 2020 – Vaccine Candidates for COVID-19
Following her presentation at CHEST 2020, entitled ‘Current Vaccine Candidates for COVID-19: Preclinical and Clinical Data’, Julie Ake (Walter Reed Army Institute of Research, Silver Spring, MD, USA) talks to touchRESPIRATORY further about vaccines in development for COVID-19. Questions What different vaccine platforms are currently being investigated for COVID-19? (0.12) How are clinical trials being harmonised and accelerated for rapid vaccine development? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!